首页> 外文期刊>ACS medicinal chemistry letters >Design, Synthesis, and Biological Evaluation of Ring-Constrained Novobiocin Analogues as Hsp90 C-Terminal Inhibitors
【24h】

Design, Synthesis, and Biological Evaluation of Ring-Constrained Novobiocin Analogues as Hsp90 C-Terminal Inhibitors

机译:设计,合成和生物评价环约束Novobiocin类似物作为Hsp90 C终端抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the treatment of cancer. Novobiocin was the first natural product identified as an Hsp90 C-terminal inhibitor; however, it manifests poor antiproliferative activity. In contrast to N-terminal inhibitors, novobiocin does not induce the pro-survival heat shock response. Structural investigations on novobiocin have elucidated some structure activity relationships and several promising compounds. On the basis of structure activity relationships and computational studies, a library of ring-constrained novobiocin analogues was designed, synthesized, and evaluated in antiproliferative assays. Results obtained from these studies provide insights into the Hsp90 C-terminal binding site, and new analogues that were developed manifest low micromolar to mid-nanomolar antiproliferative activity resulting from Hsp90 inhibition.
机译:Hsp90 C端抑制剂代表了一种新颖且替代性的癌症治疗方法。 Novobiocin是第一个被鉴定为Hsp90 C末端抑制剂的天然产物。但是,它显示出较差的抗增殖活性。与N端抑制剂相比,新生霉素不诱导生存前的热休克反应。新霉素的结构研究阐明了一些结构活性关系和一些有希望的化合物。在结构活性关系和计算研究的基础上,设计,合成并在抗增殖试验中评估了环受限的新霉素类似物的文库。从这些研究中获得的结果提供了对Hsp90 C末端结合位点的见识,并且开发的新类似物表现出由Hsp90抑制引起的低微摩尔至中纳摩尔级的抗增殖活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号